Picumast is a prophylactically active anti-allergic compound which combines inhibition of mediator release and action. The activity profile of picumast differs clearly from that of known prophylactic anti-allergic drugs such as DSCG and ketotifen. Other inhibitory actions of picumast in addition to its Histamine H1 receptor -antagonism (and that of its metabolites M2 and M1) may be the cause of the suppression of immediate and late phase allergic reactions in animals as well as allergic rhinitis and bronchial responsiveness and symptom scores in asthmatic patients. In the rat, picumast inhibited carrageenin edema but was inactive against other types of inflammation. Picumast dihydrochloride cannot be considered as an anti-inflammatory drug in general, since it was inactive against adjuvant arthritis in rats and did not inhibit cotton pellet granulomas.

Etoxeridine (Carbetidine or Wy2039), a piperidine derivative, is a narcotic analgetic.

Encenicline (EVP-6124; MT-4666) acts as a potent partial and selective agonist at alpha-7 nicotinic acetylcholine receptor. Encenicline significantly improved memory function in animal models. FORUM Pharmaceuticals (formerly EnVivo Pharmaceuticals) is developing encenicline for the treatment of cognition disorders such as schizophrenia and for Alzheimer's disease.

Sudexanox is a xanthone derivative patented by French pharmaceutical company Roussel-UCLAF for the treatment of allergy, allergic asthma, and asthmatic bronchitis. In preclinical studies, Sudexanox possesses potent activity in the IgE-induced rat passive cutaneous anaphylaxis model.

Ravuconazole is a triazole with antifungal properties that inhibits cytochrome P450 sterol 14a-demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. It was investigated for the treatment of aspergillosis, candidiasis, and onychomycosis, but these studies were discontinued. Ravuconazole is now in phase II clinical trials to investigate efficacy in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.

Olodanrigan (EMA-401) is an angiotensin II type 2 receptor antagonist. Olodanrigan may act on paracrine/autocrine mechanisms at peripheral nerve terminals, or intracrine mechanisms, to reduce neuropathic pain signalling in AngII/NGF/TRPV1-convergent pathways. Olodanrigan is being developed by Novartis for the treatment of neuropathic pain.